Tsymbaliuk V. I., Pichkur L. D., Verbovska S. А., Akinola S. Т., Vaslovich V. V., Deriabina E. G., Pokholenko I. O., Toporova O. K., Shuvalova N. S., Коrdium V. А.

EFFECT OF XENOGENEIC TRANSPLANTATION OF NATIVE GENE TRANSFECTED INTERLEUKIN 10 MESENCHYMAL STEM CELLS ON THE COURSE OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS


About the author:

Tsymbaliuk V. I., Pichkur L. D., Verbovska S. А., Akinola S. Т., Vaslovich V. V., Deriabina E. G., Pokholenko I. O., Toporova O. K., Shuvalova N. S., Коrdium V. А.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scentific article

Annotation:

The mesenchymal stem cells (MSC) of the Warton’s jelly of the human umbilical cord give immunomodulatory effects, stimulate oligodendrogenesis, secretion of anti-inflammatory cytokines, and decrease demyelinization in the central nervous system in experimental allergic encephalomyelitis (EAE). These properties can be extremely important for the correction of autoimmune states. Aim of the study. To study the influence of the umbilical cord –derived MSC and anti-inflammatory IL-10 on EAE’s course. Object and methods. The study was conducted on 46 white, non-breeding, sexually mature female rats weighing 200-230 g. The recurrent course of the EAE was induced via injection of homogenate of the rat’s spinal cord with Freund’s adjuvant (produced by “SIGMA”, USA) into the hind limb on the plantar surface. Animals were divided into 4 groups with different intravenous or subccipital injection scheme IL-10, MSC and MSCT. All animals were divided into 4 groups depending on the MSC and IL-10 treatment scheme. Synthesis of recombinant IL-10 and transfection with plasmid containing the cDNA variant of the IL-10 gene in MSC of Warton’s jelly of the human umbilical cord dangers of the 2nd passage were conducted at the Institute of Molecular Biology and Genetics of the National Academy of Sciences of Ukraine. The degree of gravity of the clinical condition was evaluated in balls. Statistical processing of the data was performed using MS Excel 2007 and STATISTICA 6.1. Results. In animals of all experimental groups, the average severity of the condition (1.3 – 1.8 points) was found at the peak of the illness (20-22 days) and the chronic remitting course of the disease. In the comparison group (No. 1), the peak of clinical manifestations was observed at 22 days. In rats of group 2 after transplantation of xenogeneous MSCs for 17 days from the induction of EAE, the state deteriorated statistically insignificantly. The peak of clinical manifestations EAE was displaced for 20 days. Next, there was a gradual regress of the EAE clinic with a complete clinical recovery for 32 days. The course of EAE up to the peak of clinical manifestations in group № 4, which received two-stage treatment with interleukin and MSC, similar to the course of EAE in group № 2. However, after subocipital administration of interleukin and MSC at day 17th, the severity of the EAE course increases significantly in the first two days followed by a statistically insignificant faster improvement compared to group № 2. A similar dynamics of recovery is observed in-group № 3, which was introduced with subocipital administration of MSCT. Acceleration of the decline of the indicator of the severity of the clinical condition in groups 3 and 4 was for both of the above-mentioned study groups – 50% on the 28-th day. Conclusions. The use of MSCT, anti-inflammatory IL-10 and MSC in various combinations promotes complete clinical healing of animals up to 32th days of experiment. Comparison of dynamic rows shows a greater efficacy of intravenous use of IL-10 for 10th day and 17th day – of MSC with IL-10 and suboccipital MSCT.

Tags:

experimental allergic encephalomyelitis, mesenchymal stem cells, interleukin-10, transfection of the gene, xenotransplantation

Bibliography:

  • Abdurakhmanova RF, Izzatov HN, Khadibayeva GR, Sharipova BA, Kakharova MH. Rasseyannyy skleroz: etiologiya, patogenez i klinika (chast I). Vestn. poslediplomnogo obrazovaniya v sfere zdravookhraneniya. 2016;3:68-74. Dostupno: http://www.vestnik-ipovszrt.tj/?p=2436 [in Russian].
  • Selmi C, Barin JG, Rose NR. Current trends in autoimmunity and the nervous system. J Autoimmun. 2016;75:20-9. DOI: 10.1016/j. jaut.2016.08.005. PMID: 27545842.
  • Pichkur LD, Verbovska SA, Akinola ST, Chytayeva HY. Osnovni patohenetychni mekhanizmy protsesu demiyelinizatsiyi v TSNS ta mozhlyvosti yoho korektsiyi. Ukr. nevrolohichnyy zhurnal. 2017;2:12-9. Dostupno: http://www. ukrneuroj.com.ua/svizhij_nomer.php?nid=43 [in Ukrainian].
  • Shmidt TE. Rasseyannyy skleroz: etiologiya, faktory riska, patogenez, klinika i progressirovaniye (po materialam kongressa Ectrims). Nevrol. zhurn. 2014;19(1):49-54. [in Russian].
  • Adami R, Scesa G, Bottai D. Stem cell transplantation in neurological diseases: improving effectiveness in animal models. Front Cell Dev Biol. 2014;2:17. DOI: 10.3389/fcell.2014.00017. PMID: 25364724. PMCID: PMC4206985.
  • Maslova OO, Shuvalova NS, Sukhorada OM, Zhukova SM, Deryabina OG, Makarenko MV, et al. Heterogeneity of Umbilical Cords as a Source for MSC. Dataset Papers in Biology. Volume 2013 (2013), Article ID 370103. Available from: http://dx.doi.org/10.7167/2013/370103
  • Dulamea AO. Role of oligodendrocyte dysfunction in demyelination, remyelination and neurodegeneration in multiple sclerosis. Adv Exp Med Biol. 2017;958:91-127. DOI: 10.1007/978-3-319-47861-6_7. PMID: 28093710.
  • Levy M, Boulis N, Rao M, Svendsen CN. Regenerative cellular therapies for neurologic diseases. Brain Res. 2016;1638(Pt A):88-96. DOI: 10.1016/j.brainres.2015.06.053. PMID: 26239912. PMCID: PMC4733583.
  • Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxiaregulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005;46(7):1339-50. DOI: 10.1016/j.jacc.2005.05.079. PMID: 16198853.
  • Zhang X, Koldzic DN, Izikson L, Reddy J, Nazareno RF, Sakaguchi S, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol. 2004;16(2):249-56. PMID: 14734610.
  • O’Neill EJ, Day MJ, Wraith DC. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J Neuroimmunol. 2006;178(1-2):1-8. DOI: 10.1016/j.jneuroim.2006.05.030. PMID: 16872684. PMCID: PMC3399771.
  • Huss DJ, Winger RC, Cox GM, Guerau-de-Arellano M, Yang Y, Racke MK, et al. TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAE. Eur J Immunol. 2011;41(10):2987-96. DOI: 10.1002/eji.201141666. PMID: 21728174. PMCID: PMC3478765.
  • Qu X, Liu X, Cheng K, Yang R, Zhao RC. Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol. 2012;40(9):761-70. DOI: 10.1016/j.exphem.2012.05.006. PMID: 22634392.
  • Pichkur LD, Kovalchuk MV, Deryabina OH, Verbovska SA, Akinola ST, Shuvalova NS, ta in. Vyzhyvannya transplantovanykh mezenkhimalʹnykh stovburovykh klityn vartonovykh drahliv pupovyny lyudyny v tsentralniy nervoviy systemi shchuriv pry eksperymentalnomu alerhichnomu entsefalomiyeliti pislya yikh suboktsypitalnoho vvedennya. Ukranian Neurosurgical Journal. 2017;3:30-5. Dostupno: http://theunj.org/article/download/112102/107234 [in Ukrainian].
  • European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes [Internet]. Council of Europe. 2017 [cited 24 May 2017]. Available from: https://rm.coe.int/168007a67b.
  • Zakon Ukrayiny «Pro zakhyst tvaryn vid zhorstokoho povodzhennya» vid 21.02.2006 No 3447-IV [Internet]. Verkhovna Rada of Ukraine. 2017 [cited 24 May 2017]. Dostupno: http://zakon2.rada.gov.ua/laws/show/3447-15 [in Ukrainian].
  • Tsymbalyuk VI, Velychko OM, Verbovska SA, Pichkur LD, Shuvalova NS. Vplyv mezenkhimalnykh stovburovykh klityn z Vartonovoho studnya pupovyny lyudyny ta interleykinu-10 na povedinkovi reaktsiyi shchuriv z eksperymentalnym alerhichnym entsefalomiyelitom. Cell and organ transplantology. 2015;3(1):40-5. DOI: 10.25305/unj.45290 [in Ukrainian].
  • Tsymbalyuk VI, Deryabina JG, Shuvalova NS, Maslova OO, Pokholenko YO, Toporova OK, ta in. Fenotypovi zminy i proliferatyvnyy potentsial mezenkhimalnykh stovburovykh klityn z Vartonovykh drahliv pupovyny lyudyny v umovakh kultyvuvannya. Ukranian Neurosurgical Journal. 2015;2:17-24. DOI: 10.25305/unj.45290 [in Ukrainian]. 
  • Okunyev OV, Palyvoda OH, Konstantynova HO, Irodov DM, Pokholenko YO. Klonuvannya interleykinu-10 lyudyny (hIL-10) ta doslidzhennya vplyvu skladu pozhyvnoho seredovyshcha na yoho syntez u klitynakh E.coli. Zbirnyk tez VII Mizhnarodnoyi naukovoyi konferentsiyi «Molod i postup biolohiyi»; 2011 April 5-8; Lviv, Ukraine. Lviv (UA): Ivan Franko National University of Lviv; 2011. s. 167. [in Ukrainian].
  • Pichkur LD, Semenova VM, Verbovska SA, Oleksenko NP, Akinola ST. Osoblyvosti perebihu eksperymentalnoho alerhichnoho entsefalomiyelitu pislya transplantatsiyi stovburovykh klityn. Ukranian Neurosurgical Journal. 2017;2:27-33. DOI: 10.25305/unj.104500 [in Ukrainian].

Publication of the article:

«Bulletin of problems biology and medicine» Issue 1 Part 2 (143), 2018 year, 227-234 pages, index UDK 575:616-089.843:611-013.395:576.3/.4:616.832-002-056.3-092.9

DOI: